Why ApoB beats LDL-C as a risk metric.

If you've had a cholesterol panel in the last decade, the number on the page is almost certainly LDL-C — the cholesterol carried by low-density lipoprotein. It's the standard. It's covered by insurance. It's what your doctor reads first. And in most cases, it tells you something true about your cardiovascular risk.

But the most useful number on a lipid panel isn't LDL-C. It's ApoB — apolipoprotein B — the count of the particles themselves. The two numbers usually agree. When they don't agree, the cases where they disagree are exactly the cases we most want to risk-stratify well: insulin resistance, metabolic syndrome, early diabetes, low HDL with high triglycerides. And in those cases, ApoB is consistently the better predictor of heart attack and stroke. Sniderman 2019

For most people reading this, the practical takeaway is short: ask for an ApoB on your next lipid panel. The longer answer — why it matters, when LDL-C alone is misleading, and what to do with the number — is below.

What each number actually measures

Cholesterol can't travel through blood by itself. It's not water-soluble. To get from the liver — where most circulating cholesterol is made — to wherever the body needs it, cholesterol is packaged inside specialised carriers: lipoproteins.

Different lipoproteins carry different mixes of cholesterol, triglycerides, and proteins. The ones that drive atherosclerosis — LDL, VLDL, IDL, and lipoprotein(a) — share one defining feature: each particle has exactly one molecule of apolipoprotein B bolted to its surface. One ApoB per atherogenic particle. Always.

This is why ApoB is the better count: it tells you how many of those particles are in your bloodstream, regardless of how much cholesterol each one happens to be carrying.

LDL-C, by contrast, measures the total cholesterol packaged inside your LDL particles. Two people can have the same LDL-C and very different ApoB — because their particles are different sizes, carrying different amounts of cholesterol each.

A two-line analogy

Imagine a fleet of trucks delivering cargo. LDL-C is the total weight of cargo crossing the bridge. ApoB is the number of trucks. If you care about how much wear and tear the bridge takes, the truck count matters more than the cargo weight — because what damages the road is each truck rolling across, not the cumulative tonnage. Mechanism

When they agree

Most of the time, LDL-C and ApoB tell the same story. Healthy adults with normal lipid metabolism tend to have particles of typical size carrying typical amounts of cholesterol. In that population, LDL-C and ApoB rise and fall together, and either one will give you a defensible read on risk.

So if you're a low-risk 30-year-old with no family history, no metabolic abnormalities, no signs of insulin resistance, and a clean panel, the ApoB will most likely confirm what your LDL-C already told you.

When they disagree — and why those cases are the ones that matter

The trouble starts when particle size and cholesterol content drift apart. Three populations consistently show this discordance:

• Insulin resistance and type 2 diabetes — particles tend to be smaller and cholesterol-poor. ApoB can be substantially elevated even when LDL-C looks reassuring.
• Hypertriglyceridaemia — high triglycerides shift particles toward the cholesterol-poor end. Same problem: LDL-C underestimates particle count.
• Patients on statins — statins lower LDL-C more than they lower particle count. A patient who looks "treated to goal" by LDL-C may still have meaningfully high ApoB. Discordance in T2D

In the largest analyses we have, ApoB is the stronger predictor of cardiovascular events than LDL-C in the discordant cases — and the discordant cases are precisely the patients we most want to identify correctly. Mora 2014 Boekholdt 2014

Atherosclerosis is driven by the number of ApoB-containing particles in circulation — and that relationship holds regardless of how, or why, those particles are elevated.

Targets — by risk tier, not by population

"Normal" ApoB depends on your risk profile. The same number that would be unremarkable in a 30-year-old with no family history would warrant action in a 45-year-old whose father had a heart attack at 56. Rough framing — these are educational targets, not prescriptions:

Numbers from professional-society guidelines and the published threshold literature, simplified for orientation. EAS 2020

What to ask for, and how

If your last panel was LDL-C only, three practical moves:

1. Ask explicitly for ApoB at your next blood draw. Most labs run it. Cost is typically $10–30. Insurance often covers it; if it doesn't, the out-of-pocket is small.
2. Ask for Lp(a) once in your life. Lp(a) is genetically determined and doesn't change much across adulthood — a single measurement is usually enough. Elevated Lp(a) raises ApoB-particle risk independently and changes your target tier.
3. Ask your physician what the number means in your specific context. The framework above is for orientation; your doctor knows your full picture.

If ApoB is so much better, why isn't it standard?

Three real reasons, none of which mean LDL-C is wrong:

• The historical evidence base for cardiovascular risk and statin response was built on LDL-C. It's the number embedded in five decades of trials and guidelines.
• LDL-C is calculated, not directly measured, in the most common panel — which means it's effectively free. ApoB is a separate assay.
• Professional guidelines have been slow to catch up. Some societies (notably the European Atherosclerosis Society) now place ApoB equal to or above LDL-C; others still treat it as supplementary. Guideline divergence

The direction of travel is clearly toward ApoB. Your physician may already be running it. If they're not, you can ask — politely, prepared, and with the understanding that the goal is a better picture of your risk, not a fight about lab orders.